ValuEngine Lowers Ra Pharmaceuticals (RARX) to Hold

ValuEngine cut shares of Ra Pharmaceuticals (NASDAQ:RARX) from a buy rating to a hold rating in a research report sent to investors on Thursday.

Other equities research analysts have also issued reports about the stock. BMO Capital Markets started coverage on shares of Ra Pharmaceuticals in a report on Friday, July 20th. They issued an outperform rating and a $20.00 target price for the company. BidaskClub upgraded Ra Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, October 19th. Zacks Investment Research upgraded Ra Pharmaceuticals from a hold rating to a buy rating and set a $12.00 price target for the company in a research note on Tuesday, August 14th. Credit Suisse Group set a $25.00 price target on Ra Pharmaceuticals and gave the stock a buy rating in a research note on Friday, October 19th. Finally, Raymond James upgraded Ra Pharmaceuticals from an outperform rating to a strong-buy rating and set a $28.00 price target for the company in a research note on Wednesday, October 10th. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Ra Pharmaceuticals has a consensus rating of Buy and a consensus target price of $20.80.

Ra Pharmaceuticals stock traded down $0.35 during midday trading on Thursday, hitting $11.97. The stock had a trading volume of 356,625 shares, compared to its average volume of 240,946. The firm has a market capitalization of $446.62 million, a price-to-earnings ratio of -4.97 and a beta of 2.08. Ra Pharmaceuticals has a 52-week low of $4.78 and a 52-week high of $19.43.

Ra Pharmaceuticals (NASDAQ:RARX) last released its earnings results on Wednesday, November 7th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.02). As a group, analysts predict that Ra Pharmaceuticals will post -2.14 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of RARX. Cubist Systematic Strategies LLC boosted its position in shares of Ra Pharmaceuticals by 817.8% during the 1st quarter. Cubist Systematic Strategies LLC now owns 19,999 shares of the company’s stock valued at $106,000 after acquiring an additional 17,820 shares during the last quarter. Gabelli Funds LLC bought a new position in shares of Ra Pharmaceuticals during the 2nd quarter valued at approximately $120,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Ra Pharmaceuticals during the 1st quarter valued at approximately $128,000. Nisa Investment Advisors LLC bought a new position in shares of Ra Pharmaceuticals during the 2nd quarter valued at approximately $157,000. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Ra Pharmaceuticals by 50.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 32,800 shares of the company’s stock valued at $175,000 after acquiring an additional 11,000 shares during the last quarter. Hedge funds and other institutional investors own 73.36% of the company’s stock.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Featured Article: Dow Jones Industrial Average (DJIA)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply